Rh2 further significantly inhibited the proliferation of primary AML cells treated with sTRAIL or zA4 (Fig. 7f, g), which induced the expression of the TRAIL-related receptors DR4, DR5, and DcR1 (Fig. 7h). Here, RHAG is linked to acute myeloid leukemia.